vida: extract claims from 2026-04-24-compass-pathways-fda-rolling-nda-priority-voucher-comp360

- Source: inbox/queue/2026-04-24-compass-pathways-fda-rolling-nda-priority-voucher-comp360.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/ibogaine-federal-policy-priority-rests-on-single-n30-pilot-illustrating-veteran-constituency-acceleration-ahead-of-evidence-hierarchy.md

@@ -10,15 +10,17 @@ agent: vida
 sourced_from: health/2024-xx-stanford-ibogaine-veterans-ptsd-n30.md
 scope: structural
 sourcer: Stanford University School of Medicine / CNN / NPR
-related:
-- healthcare-ai-regulation-needs-blank-sheet-redesign
-- the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access
-supports:
-- Stanford Ibogaine Veterans Study
-reweave_edges:
-- Stanford Ibogaine Veterans Study|supports|2026-05-11
+related: ["healthcare-ai-regulation-needs-blank-sheet-redesign", "the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access", "ibogaine-federal-policy-priority-rests-on-single-n30-pilot-illustrating-veteran-constituency-acceleration-ahead-of-evidence-hierarchy", "stanford-ibogaine-veterans-study", "trump-2026-psychedelic-executive-order-creates-bipartisan-regulatory-acceleration-through-existing-frameworks"]
+supports: ["Stanford Ibogaine Veterans Study"]
+reweave_edges: ["Stanford Ibogaine Veterans Study|supports|2026-05-11"]
 ---
 
 # Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies
 
-The Stanford ibogaine study enrolled 30 veterans with PTSD, TBI, and/or substance use disorder in an overseas clinical setting (ibogaine is Schedule I in the US). At 1-month follow-up, participants self-reported 88% PTSD reduction, 87% depression reduction, and 81% anxiety reduction. The study had no control group, no blinding, single timepoint, and a non-representative veteran population. Despite these severe evidence limitations, Trump's April 2026 executive order specifically named ibogaine for veterans and allocated $50M in ARPA-H funding. Ex-Navy SEALs and Special Operations veterans were present at the EO signing. This represents a case where a small pilot study with compelling effect sizes in a politically salient population (veterans) drove federal policy and funding commitments ahead of the standard evidence hierarchy that would require Phase 2 and Phase 3 trials. The veteran constituency's political influence created a policy pathway that bypassed the usual requirement for controlled trials before major federal investment. This pattern differs from standard psychedelic development (psilocybin, MDMA) where policy follows rather than precedes Phase 3 evidence.
+The Stanford ibogaine study enrolled 30 veterans with PTSD, TBI, and/or substance use disorder in an overseas clinical setting (ibogaine is Schedule I in the US). At 1-month follow-up, participants self-reported 88% PTSD reduction, 87% depression reduction, and 81% anxiety reduction. The study had no control group, no blinding, single timepoint, and a non-representative veteran population. Despite these severe evidence limitations, Trump's April 2026 executive order specifically named ibogaine for veterans and allocated $50M in ARPA-H funding. Ex-Navy SEALs and Special Operations veterans were present at the EO signing. This represents a case where a small pilot study with compelling effect sizes in a politically salient population (veterans) drove federal policy and funding commitments ahead of the standard evidence hierarchy that would require Phase 2 and Phase 3 trials. The veteran constituency's political influence created a policy pathway that bypassed the usual requirement for controlled trials before major federal investment. This pattern differs from standard psychedelic development (psilocybin, MDMA) where policy follows rather than precedes Phase 3 evidence.
+
+## Supporting Evidence
+
+**Source:** ARPA-H EVIDENT announcement, April 24, 2026
+
+Texas IMPACT consortium receives $100M total funding ($50M state + $50M ARPA-H match) for ibogaine research, representing the largest single psychedelic research investment to date. This funding level—allocated before Phase 3 completion—confirms that veteran constituency political priority is driving resource allocation ahead of traditional evidence hierarchy requirements.

domains/health/psilocybin-achieves-positive-phase3-trd-single-dose-26week-durability.md

@@ -32,3 +32,10 @@ Oregon's real-world implementation shows facilitators specializing in trauma (83
 **Source:** Bendable Therapy Oregon Measure 109 study, March 2024-April 2025
 
 Oregon real-world naturalistic study shows large effect sizes at 30-day follow-up (PHQ-8: -4.63 points, d=0.90; GAD-7: -4.85 points, d=1.04; WHO-5: +10.67 points, d=2.14) with average dose 27.8mg TPE. However, follow-up limited to 30 days, preventing durability comparison with Compass Phase 3's 26-week endpoint. Study population differs from treatment-resistant depression trials: only 51.1% had depression diagnosis, 64.8% had prior psilocybin experience, and clients were self-selected paying customers rather than trial participants.
+
+
+## Extending Evidence
+
+**Source:** Compass Pathways press release, April 24, 2026
+
+COMP360 completed two consecutive positive Phase 3 trials (COMP005 n=258, COMP006 n=568), becoming the first psychedelic to achieve this milestone. COMP006 showed 39% response rate vs 23% control with rapid onset from next day, and 40%+ of non-remitters achieved remission after second dose. FDA granted rolling NDA review and Commissioner's National Priority Voucher, compressing review timeline to 1-2 months (vs standard 6-12 months). Rolling NDA completion expected Q4 2026, with potential FDA approval as early as Q4 2026-Q1 2027.

domains/health/trump-2026-psychedelic-executive-order-creates-bipartisan-regulatory-acceleration-through-existing-frameworks.md

@@ -10,17 +10,18 @@ agent: vida
 sourced_from: health/2026-04-18-trump-executive-order-psychedelics-mental-health.md
 scope: structural
 sourcer: White House / FDA
-challenges:
-- healthcare-ai-regulation-needs-blank-sheet-redesign
-related:
-- healthcare-ai-regulation-needs-blank-sheet-redesign
-- fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness
-supports:
-- Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies
-reweave_edges:
-- Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies|supports|2026-05-11
+challenges: ["healthcare-ai-regulation-needs-blank-sheet-redesign"]
+related: ["healthcare-ai-regulation-needs-blank-sheet-redesign", "fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness", "trump-2026-psychedelic-executive-order-creates-bipartisan-regulatory-acceleration-through-existing-frameworks", "ibogaine-federal-policy-priority-rests-on-single-n30-pilot-illustrating-veteran-constituency-acceleration-ahead-of-evidence-hierarchy", "psilocybin-achieves-positive-phase3-trd-single-dose-26week-durability"]
+supports: ["Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies"]
+reweave_edges: ["Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies|supports|2026-05-11"]
 ---
 
 # Trump's April 2026 Executive Order on psychedelics represents the first federal bipartisan commitment to Schedule I psychedelic drug development pathways, signaling regulatory environment shift that de-risks clinical investment through existing frameworks rather than new legislation
 
-The Executive Order issued April 18, 2026 creates three procedural accelerations for psychedelic drug development: (1) FDA National Priority Vouchers issued to Compass Pathways (COMP360 psilocybin), Usona Institute (psilocybin), and Transcend Therapeutics (methylone TSND-201) compress review timelines to 1-2 months post-application; (2) FDA and DEA directed to establish Right to Try pathway for psilocybin and ibogaine, allowing pre-approval access for seriously ill patients; (3) $50 million ARPA-H funding to match state investments in psychedelic research, specifically naming ibogaine for veterans. Critically, the EO does NOT change Schedule I status, does NOT approve any drug, and does NOT create enforceable patient rights—it operates entirely within existing regulatory frameworks. The political significance is structural: a Republican administration accelerating Schedule I drug pathways represents bipartisan momentum driven by veteran advocacy groups (ex-Navy SEALs present at signing ceremony). This de-risks clinical investment by providing procedural clarity and expedited review pathways without requiring legislative change. The FDA responded within 6 days by issuing the three priority vouchers, demonstrating immediate implementation. The regulatory posture shift is from experimental-to-expedited rather than prohibited-to-permitted.
+The Executive Order issued April 18, 2026 creates three procedural accelerations for psychedelic drug development: (1) FDA National Priority Vouchers issued to Compass Pathways (COMP360 psilocybin), Usona Institute (psilocybin), and Transcend Therapeutics (methylone TSND-201) compress review timelines to 1-2 months post-application; (2) FDA and DEA directed to establish Right to Try pathway for psilocybin and ibogaine, allowing pre-approval access for seriously ill patients; (3) $50 million ARPA-H funding to match state investments in psychedelic research, specifically naming ibogaine for veterans. Critically, the EO does NOT change Schedule I status, does NOT approve any drug, and does NOT create enforceable patient rights—it operates entirely within existing regulatory frameworks. The political significance is structural: a Republican administration accelerating Schedule I drug pathways represents bipartisan momentum driven by veteran advocacy groups (ex-Navy SEALs present at signing ceremony). This de-risks clinical investment by providing procedural clarity and expedited review pathways without requiring legislative change. The FDA responded within 6 days by issuing the three priority vouchers, demonstrating immediate implementation. The regulatory posture shift is from experimental-to-expedited rather than prohibited-to-permitted.
+
+## Supporting Evidence
+
+**Source:** ARPA-H EVIDENT announcement, April 24, 2026
+
+ARPA-H's EVIDENT initiative operationalizes the Trump April 18, 2026 EO directive for federal matching of state psychedelic research investments. Texas IMPACT consortium receives $50M state funding matched by $50M ARPA-H federal funding for ibogaine research, demonstrating the EO's matching mechanism is now active and funded. The initiative also incorporates international data (Diamond Therapeutics, Canadian company) into US regulatory pathways, showing cross-border evidence integration.

entities/health/arpa-h-evident.md

@@ -0,0 +1,46 @@
+# ARPA-H EVIDENT Initiative
+
+**Full name:** Evidence-Based Validation & Innovation for Rapid Therapeutics in Behavioral Health (EVIDENT)
+
+**Parent organization:** Advanced Research Projects Agency for Health (ARPA-H)
+
+**Total funding:** Up to $139.4 million
+
+**Launch date:** April 24, 2026
+
+**Mission:** Generate FDA-ready clinical endpoints for rapid-acting behavioral health therapies across three modalities: digital interventions, neuromodulation, and neuroplastogens (including psychedelics).
+
+## Program Structure
+
+**Psychedelic research component:**
+- Minimum $50M allocated to match qualifying state government investments in psychedelic research for serious mental illness populations
+- Implements federal matching mechanism from Trump April 18, 2026 Executive Order on psychedelics
+- Texas IMPACT consortium: $50M state + $50M ARPA-H federal match = ~$100M total for ibogaine research
+
+**Selected research teams:**
+- **INVI MindHealth** (Denver): Real-time biomarker platform for neuromodulation + psychedelic therapies
+- **Diamond Therapeutics** (Toronto): Contributing Phase 2a psilocybin data for generalized anxiety disorder (GAD)
+- **University of Wisconsin**: Contributing data from 3 approved psilocybin trials
+
+**Award structure:** Rolling basis announcements for future teams
+
+## Strategic Context
+
+**ARPA-H vs. NIH distinction:** ARPA-H operates on DARPA-like model—time-limited, mission-driven, risk-tolerant. Unlike NIH RO1 grants, ARPA-H funds teams to produce specific regulatory-ready endpoints rather than open-ended research.
+
+**Regulatory pathway:** EVIDENT produces clinical evidence → FDA approval → CMS coverage review → reimbursement. Initiative only accelerates first step (evidence generation), not subsequent access barriers.
+
+## Timeline
+
+- **2026-04-18** — Trump Executive Order directs ARPA-H to match state psychedelic research investments
+- **2026-04-24** — ARPA-H announces EVIDENT initiative with $139.4M total funding, including $50M+ psychedelic research matching component
+- **2026-04-24** — First research teams announced: INVI MindHealth, Diamond Therapeutics, University of Wisconsin
+- **2026-04-24** — Texas IMPACT consortium $100M ibogaine research funding confirmed ($50M state + $50M federal match)
+
+## Analysis
+
+EVIDENT represents the first systematic federal investment vehicle for psychedelic-assisted therapy research, transitioning funding from private pharmaceutical companies (Compass, Usona) and philanthropy (MAPS) to government-backed infrastructure. The $139.4M allocation is modest by NIH standards but leveraged through ARPA-H's mandate to produce FDA-ready endpoints rather than general research outputs.
+
+Notably, the initiative incorporates international data (Diamond Therapeutics, Canadian company) into US regulatory pathways, demonstrating cross-border evidence integration. The GAD indication for Diamond's psilocybin trial addresses a larger population (~40M US sufferers) than treatment-resistant depression or PTSD.
+
+Critical gap: EVIDENT focuses exclusively on evidence generation without addressing reimbursement, workforce training, or care delivery infrastructure—the binding constraints on patient access post-approval.

entities/health/comp006-trial.md

@@ -0,0 +1,28 @@
+# COMP006 Trial
+
+**Type:** Phase 3 randomized controlled trial  
+**Sponsor:** Compass Pathways  
+**Intervention:** COMP360 (synthetic psilocybin)  
+**Indication:** Treatment-resistant depression (TRD)  
+**Status:** Completed (results announced February 2026)  
+
+## Design
+- **N = 568** participants
+- **Arms:** 25mg vs 10mg vs 1mg (placebo-like control)
+- **Dosing:** 2 doses administered 3 weeks apart
+- **Primary endpoint:** MADRS change from baseline
+
+## Results
+- **Primary endpoint met:** MADRS change -3.8 points vs control (p<0.001)
+- **Response rate:** 39% vs 23% control at week 6
+- **Onset:** Rapid improvement from next day post-dose
+- **Second dose benefit:** 40%+ of non-remitters after first dose achieved remission after second dose
+- **Durability:** Part B 26-week durability data expected early Q3 2026
+
+## Significance
+COMP006 is the second consecutive positive Phase 3 trial for COMP360, making it the first psychedelic compound to achieve two positive Phase 3 results. Combined with COMP005, this formed the basis for FDA rolling NDA review and Commissioner's National Priority Voucher (April 2026).
+
+## Timeline
+- **2026-02** — Results announced
+- **2026-04-24** — FDA granted rolling NDA review based on COMP005 + COMP006 data
+- **2026-Q3** — Part B 26-week durability data expected (final dataset for NDA)

entities/health/diamond-therapeutics.md

@@ -0,0 +1,28 @@
+# Diamond Therapeutics
+
+**Location:** Toronto, Canada
+
+**Focus:** Psilocybin-assisted therapy for anxiety disorders
+
+**Stage:** Phase 2a clinical trials
+
+## Clinical Programs
+
+**Generalized Anxiety Disorder (GAD):**
+- Phase 2a psilocybin trial data being contributed to ARPA-H EVIDENT initiative
+- GAD represents largest single anxiety disorder population (~40M US sufferers)
+- Larger addressable market than treatment-resistant depression (TRD) or PTSD
+
+## Strategic Position
+
+Diamond Therapeutics is notable as a Canadian company selected for US government-funded research infrastructure (ARPA-H EVIDENT), demonstrating international data integration into US regulatory pathways. The GAD indication differentiates from most psychedelic research focused on depression or PTSD.
+
+## Timeline
+
+- **2026-04-24** — Selected as ARPA-H EVIDENT research team, contributing Phase 2a psilocybin GAD trial data
+
+## Analysis
+
+The GAD indication is strategically significant: if psilocybin demonstrates efficacy for generalized anxiety disorder, the addressable population exceeds TRD and PTSD combined. GAD affects ~6.8M US adults annually (3.1% of population), with lifetime prevalence near 9%. Current first-line treatments (SSRIs, SNRIs, benzodiazepines) have limited efficacy and significant side effect profiles, creating unmet medical need.
+
+Diamond's inclusion in ARPA-H EVIDENT despite being a non-US company indicates that psychedelic research infrastructure is genuinely international, with US regulatory agencies willing to incorporate foreign clinical data into domestic approval pathways.

entities/health/invi-mindhealth.md

@@ -0,0 +1,32 @@
+# INVI MindHealth
+
+**Location:** Denver, Colorado
+
+**Focus:** Real-time biomarker platform for neuromodulation and psychedelic therapies
+
+**Stage:** Selected for ARPA-H EVIDENT initiative
+
+## Technology Platform
+
+Real-time biomarker monitoring system designed to:
+- Track physiological responses during neuromodulation treatments
+- Monitor psychedelic therapy sessions
+- Generate FDA-ready clinical endpoint data
+
+## Strategic Position
+
+INVI MindHealth represents the biomarker infrastructure layer for behavioral health interventions—addressing the measurement gap that has historically limited psychedelic and neuromodulation research. Real-time monitoring enables:
+1. Objective outcome measurement beyond self-reported scales
+2. Safety monitoring during treatment sessions
+3. Dose-response optimization
+4. Mechanistic understanding of therapeutic effects
+
+## Timeline
+
+- **2026-04-24** — Selected as ARPA-H EVIDENT research team for real-time biomarker platform development
+
+## Analysis
+
+The biomarker platform addresses a critical gap in psychedelic research: functional unblinding (patients and clinicians knowing who received active drug) invalidates self-reported outcomes in highly psychoactive compounds. Objective biomarkers could provide unblinding-resistant endpoints, strengthening regulatory submissions.
+
+ARPA-H's selection of a biomarker platform company (rather than only drug developers) signals recognition that measurement infrastructure is a binding constraint on FDA approval pathways for behavioral health interventions.

entities/health/texas-impact-consortium.md

@@ -1,71 +1,38 @@
----
-type: entity
-entity_type: research_program
-name: Texas IMPACT Consortium
-full_name: Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma
-domain: health
-status: active
-founded: 2025-12
-headquarters: Texas, USA
-website: null
-tags: [ibogaine, OUD, PTSD, TBI, psychedelic, clinical-trial, Texas]
----
+# Texas IMPACT Consortium
 
-## Overview
+**Full name:** Texas Ibogaine Multi-site Program for Addiction and Combat Trauma (IMPACT)
 
-The Texas IMPACT (Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma) Consortium represents the largest state-sponsored psychedelic research investment in US history, with $50 million from Texas Health and Human Services Commission plus up to $50 million ARPA-H federal match for a potential $100 million total.
+**Location:** Texas
 
-## Structure
+**Total funding:** ~$100 million ($50M state + $50M ARPA-H federal match)
 
-**Lead institutions:** UTHealth Houston and UTMB Health (Galveston)
+**Focus:** Ibogaine research for addiction and combat-related trauma in veteran populations
 
-**Consortium members (11 institutions):**
-- UTHealth Houston
-- UTMB Health
-- Texas Tech University
-- Texas Tech UTHS El Paso
-- UT Austin
-- UT Health Science Center San Antonio
-- UT Tyler
-- UT Rio Grande Valley
-- Texas A&M University
-- University of North Texas Health Science Center
-- Baylor College of Medicine
-- JPS Health Network (Dallas)
+## Funding Structure
 
-## Research Design
+**State investment:** $50 million from Texas state government
 
-**Duration:** Two-year multicenter trial (Phase 2 scale)
+**Federal match:** $50 million from ARPA-H EVIDENT initiative, implementing Trump April 18, 2026 Executive Order matching mechanism
 
-**Conditions targeted:**
-- Opioid use disorder (primary indication) — UTHealth Houston + UTMB
-- Traumatic brain injury — UT Austin + Baylor College of Medicine
-- PTSD — coordinated across sites
+**Total:** ~$100 million—largest single psychedelic research investment to date
 
-**Key evidence basis:**
-- Stanford 2024 study (n=30 veterans): 88% PTSD reduction, 87% depression reduction at 1 month
-- MAPS Phase 2 OUD: 70-75% abstinence at 1 month
-- Mechanism: Opioid receptor reset + GDNF production → dopaminergic neuron regeneration
-- Unique capability: Abolishes opioid withdrawal symptoms within 1-2 days
+## Strategic Context
 
-## Regulatory Context
+**Political constituency:** Veteran-focused research transcends partisan politics, enabling conservative state (Texas) to lead psychedelic research investment. Veteran constituency provides political cover for Schedule I substance research.
 
-**Current status:** Ibogaine is Schedule I (federal) with no completed Phase 3 trial in US
+**Evidence base:** Funding allocated before Phase 3 completion, based primarily on Stanford n=30 pilot study, illustrating constituency-driven acceleration ahead of traditional evidence hierarchy.
 
-**Safety barrier:** QT prolongation risk with >30 documented deaths in unsupervised settings
-
-**Political support:**
-- Texas SB 2308 (December 2025): Authorized $50M state funding
-- Trump EO (April 2026): Directed ARPA-H funding toward ibogaine for veterans; DEA to initiate rescheduling upon Phase 3 completion
-- Colorado Proposition 122: Decriminalized in Colorado
+**Indication focus:** Opioid use disorder (OUD) and combat-related PTSD in veteran populations
 
 ## Timeline
 
-- **2025-12** — Texas SB 2308 authorizes $50M state funding for IMPACT consortium
-- **2026-04** — Trump executive order directs ARPA-H to provide up to $50M federal match and commits DEA to rescheduling process upon Phase 3 completion
+- **2026-04-18** — Trump Executive Order directs ARPA-H to match state psychedelic research investments
+- **2026-04-24** — Texas IMPACT consortium funding confirmed: $50M state + $50M ARPA-H federal match
 
-## Significance
+## Analysis
 
-The Texas IMPACT consortium addresses the opioid overdose crisis (79,384 deaths in 2024), the most acute public health emergency in mental health/substance use. Ibogaine is the only psychedelic with credible single-session evidence for OUD specifically. The program demonstrates bipartisan political support through veteran-focused framing, with conservative Texas authorizing the largest state psychedelic research investment in US history.
+The $100M total funding represents the largest single psychedelic research investment in history, exceeding all prior private pharmaceutical and philanthropic investments in individual psychedelic programs. The funding level—allocated before Phase 3 completion—demonstrates that veteran constituency political priority is overriding traditional evidence hierarchy requirements.
 
-Realistic FDA approval timeline: 2029-2030 if Phase 2 data supports Phase 3 advancement, making ibogaine 4-5 years behind psilocybin despite addressing higher-mortality condition.
+Texas as the lead state is strategically significant: conservative state leadership in psychedelic research signals bipartisan political viability when framed through veteran healthcare rather than counterculture associations.
+
+Ibogaine's cardiac safety concerns (QT prolongation, arrhythmia risk) remain the primary regulatory barrier. The IMPACT consortium funding likely includes cardiac safety protocol development (IV magnesium co-administration, continuous monitoring) to address FDA approval pathway requirements.

inbox/archive/health/2026-04-24-arpa-h-evident-139m-behavioral-health-psychedelics.md

@@ -7,10 +7,13 @@ date: 2026-04-24
 domain: health
 secondary_domains: []
 format: government-announcement
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-11
 priority: medium
 tags: [ARPA-H, behavioral-health, psychedelics, psilocybin, federal-funding, mental-health, research]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-04-24-compass-pathways-fda-rolling-nda-priority-voucher-comp360.md

@@ -7,10 +7,13 @@ date: 2026-04-24
 domain: health
 secondary_domains: []
 format: press-release
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-11
 priority: high
 tags: [psilocybin, Compass-Pathways, FDA, NDA, COMP360, TRD, regulatory, psychedelic, approval-timeline]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content